



## Press release

### Dr. Steffen Wagner to become Head of Europe for the STADA Group

Bad Vilbel, April 16, 2018 – Dr. Steffen Wagner is to become the Head of Europe for the STADA Group as of July 1, 2018. “I am very much looking forward to supporting STADA on its growth trajectory and in implementing its corporate strategy,” said Wagner.

“Steffen Wagner will be a crucial addition to our leadership team,” said STADA’s CEO Dr. Claudio Albrecht. “He will be assuming the overall responsibility for all markets in Europe except Germany, the UK, and Russia, and he will report directly to me.” STADA’s strategy is focused on the three pillars of generics, non-prescription products and specialty pharmaceuticals including biosimilars, with an emphasis on diabetes, the central nervous system, oncology and ophthalmology. “Steffen Wagner’s experience makes him a perfect fit for the role,” said Albrecht.

Prior to joining STADA Wagner was the Managing Director of Biogen Germany. There he was involved in the implementation of the company’s growth strategy as one of Germany’s fastest growing pharmaceutical companies. Thanks to his experience at Sandoz and Biogen, Wagner is also considered an expert on biosimilars.

From 2009 to 2016, Wagner held various positions with increasing responsibility within the Novartis Group, most recently as Area Vice President for Emerging Growth Markets at Alcon, the Novartis Group’s ophthalmology division. In this position, he oversaw markets in Eastern Europe, the Middle East, and Africa. His experience at Sandoz is also particularly relevant, where he was involved in company strategy, biosimilars, and held operational business responsibility at international and country levels. From 2005 to 2009, Wagner was a management consultant for Bain & Company and McKinsey & Company with a specific focus on pharmaceutical industry. Wagner studied medicine at LMU in Munich, is 40 years old, married and has one child.

Executive Board: Dr. Claudio Albrecht (Chairman) / Mark Keatley / Dr. Barthold Piening  
Chairman of the Supervisory Board: Dr. Günter von Au



### **About STADA Arzneimittel AG**

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, non-prescription OTC products and specialty pharmaceuticals, biosimilars in particular. Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2017, STADA achieved adjusted Group sales of Euro 2,255.3 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 433.9 million and adjusted net income of Euro 195.6 million. As of December 31, 2017, STADA employed 10,176 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /

Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: [press@stada.de](mailto:press@stada.de)

Or visit us in the Internet at [www.stada.com](http://www.stada.com)

Executive Board: Dr. Claudio Albrecht (Chairman) / Mark Keatley / Dr. Barthold Piening  
Chairman of the Supervisory Board: Dr. Günter von Au